340 results about "Lipofectamine" patented technology

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

Liposomes encapsulating a radioisotope can be used in the treatment of cancers including, but not limited to, leptomeningeal metastases. In an embodiment, liposome encapsulating a radioisotope comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the liposome encapsulating a radioisotopе concomitant or subsequent to administration. Longitudinal analysis of the presence of tumor cells and biomarkers can be used to inform treatment strategy.

The invention relates to the technical field of biological medicine, and discloses a nano composite adjuvant as well as a preparation method and application thereof. The composite adjuvant mainly comprises a TLR9 agonist CpG ODN, a nanoscale liposome, a cationic lipid DOTAP and a high-efficiency immunologic stimulant QS-21, several adjuvant components are prepared into the stable and uniform nanoscale liposome by adopting a microfluidic synthesis method, CpG is wrapped inside the nanoscale liposome, QS-21 is adsorbed outside the nanoscale liposome, a stable immunologic stimulation compound is formed, and the immunologic stimulant can be used for immunologic detection of the TLR9 agonist CpG ODN, the cationic lipid DOTAP and the high-efficiency immunologic stimulant QS-21. All the components have a remarkable synergistic effect, and are matched with corresponding antigens to generate strong and lasting cellular immune and humoral immune responses.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The application discloses a detection method of cell surface antigens and application thereof, and relates to the detection field. The detection method of cell surface antigens comprises the following steps: mixing liposome-treated cells to be detected with capture microspheres and fluorescent microspheres, detecting the fluorescence intensity, and analyzing the expression of cell surface antigens. The surface of the capture microspheres is coated with a first antibody against a specific antigen on the surface of target cells. The surface of the fluorescent microspheres is coated with a second antibody against a target antigen on the surface of target cells. The detection method has low cost and can be used for directly quantitatively and qualitatively analyzing the expression of surface antigens of specific types of cells.

The present invention relates to an mRNA vaccine composition for the prevention of enterovirus A71 (EV-A71) infection. The composition comprises an mRNA encoding the VP1 protein of EV-A71 and lipid nanoparticles (LNPs) comprising specific cationic lipids. Compared with the conventional cationic lipid system, the imidazopyridyl cationic lipid A5 with strong membrane fusion capability is adopted, so that obvious neutralizing antibody and cellular immune response can be induced under single-time and low-dose immune conditions, and excellent safety and children applicability are shown.

The invention belongs to the technical field of cosmetics, and particularly relates to a cell energy activation composition with an anti-aging effect and a preparation method thereof, the cell energy activation composition with the anti-aging effect and the preparation method thereof are characterized in that the cell energy activation composition with the anti-aging effect comprises the following components: 3-10 parts of thiotaurine and 0.01-0.5 part of a metal ion compound, the composition is prepared from the following raw materials in parts by weight: 0.05-0.5 part of an antioxidant, 0.005-0.05 part of redox regulatory protein, 0.1-6 parts of a raw grass-containing extract, 0.01-1 part of 4-tert-butyl cyclohexanol and 0.05-3 parts of a lipidosome delivery system, according to the invention, multi-channel energy activation is carried out: thiotaurine participates in energy metabolism, metal ions promote enzyme activity, thioredoxin maintains redox balance, and mitochondrial functions are comprehensively improved; liposomal delivery enhances absorption: the transdermal ability of active matters is improved, the stability is enhanced, and the utilization rate is increased; multiple anti-aging mechanisms are as follows: oxidation resistance, saccharification resistance and cell repair.

The present invention relates to an acoustofluidic micromixing platform (1) used for the synthesis of ultra-small liposome nanoparticles and related nano-bio materials.

Various formulations for combination therapy of liposomes and SR-BI inhibitors that result in enhanced liposome uptake by target cells are provided, exemplified by combination therapy with CPX-351 and BLT-1. Also provided are various formulations for combination therapy of liposomes and ENT inhibitors that result in enhanced uptake of liposome-encapsulated cytarabine by target cells. Also provided are methods for using the formulations in combination therapy. Also provided are methods for reducing cardiotoxicity in age-group patient populations receiving therapy with cytarabine and daunorubicin, and CPX-351.

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The present invention relates to the use of a therapeutic agent based on cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex for the preparation of a drug for the treatment of patients with active tuberculosis.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

Tolerogenic liposome-based compositions and uses thereof for treating immune disorders. The compositions include two populations of liposomes. The first population of liposomes has a size in the range from 2 to 200 nm, and the second population of liposomes has a size in the range from 500 to 2000 nm. The liposomes of the first and second populations carry one or more antigens. The liposomal membrane of each liposome in the first and second liposome populations include phosphatidylserine in an amount ranging from 20 to 60% by weight with respect to the total composition of the liposome's membrane.

The present invention provides, in part, a cationic lipid based on tris (hydroxymethyl) methylglycine and citric acid having an aromatic head group having formula (I) and its sub-formula: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be used to deliver and express mRNA and encoded proteins, for example, as components of liposomal delivery vehicles, and thus can be used to treat various diseases, disorders, and conditions, such as those associated with the lack of one or more proteins. (I)

The invention discloses a fresh-keeping storage method of plum fruits, which is characterized in that a compact network structure of a shellac-pullulan-gellan gum basic composition effectively obstructs invasion of external microorganisms, and significantly slows down loss of water in the fruits, so that the plump appearance and hardness of the fruits are maintained, and the fruit quality is improved. The siRNA and the AVG wrapped by the lipidosome accurately interfere with the ripening and senescence process in the fruit from the molecular level, the siRNA specifically silences the gene expression of cell wall degradation key enzyme and delays the softening process of the fruit, and the AVG effectively blocks the biosynthesis pathway of ethylene and inhibits the start of an after-ripening signal, so that the ripening and senescence process of the fruit is delayed. The external formed physical film provides a stable microenvironment for internal bioactive molecules, protects the internal bioactive molecules from being degraded and prolongs the action time, and the internal molecular regulation delays the disintegration of cell structures, so that the external film can be attached more enduringly and exerts a barrier function, and the maintenance of the fruit quality is realized under a refrigeration condition.

The invention provides a gene editing cell and a method for producing extremely high molecular weight hyaluronic acid by using the cell. The preparation method comprises the following steps: by taking PUC57 as a skeleton carrier, constructing a recombinant plasmid containing an HAS2 gene, and transfecting a mole NMRHas2 gene, a chicken CHICKHAS2 gene, an astronomy mouse SNMHAS2 gene, a dakalimeris mouse DMRHAS2 gene or a mole mouse BMRHAS2 gene into chicken fibroblasts through lipidosome to construct a stably transfected cell line, so that hyaluronic acid with extremely high molecular weight can be stably obtained. The method provided by the invention overcomes the defects of non-uniform molecular weight distribution of HA product sources, low molecular weight and single method in the prior art, and has important significance for developing medicines for treating osteoarthritis and novel medical equipment products.

Methods for manufacturing a non-viral delivery system comprising a liposome encapsulating an RNA using a microfluidic device and compositions for use therein are provided.

The application discloses a preparation method of a photoelectrochemical immunosensor for detecting carcinoembryonic antigen + The signal amplification strategy of liposomes and Bi2S3@BiOI heterojunction as a base material are used to successfully construct a PEC immunosensor of Bi2S3@BiOI / Ag2S ternary heterojunction, and the PEC immunosensor is used for detecting the content of carcinoembryonic antigen. Specifically, a sandwich immunocomplex is formed through specific recognition of the aptamer fixed on the magnetic beads, the aptamer labeled on the liposomes and CEA, methanol as a demulsifier is added, the liposomes are broken to release a large number of signal molecules Ag + . The released Ag + is transferred to the surface of the electrode modified by Bi2S3@BiOI to form Ag2S with a narrow band gap in situ, the ternary heterojunction of Bi2S3@BiOI / Ag2S is formed due to the existence of the energy level matching relationship, the light absorption range is expanded, the separation of photoinduced electron-hole pairs is accelerated, the photocurrent signal is enhanced, and the purpose of signal amplification is achieved.

An antibody-conjugated liposome, particularly a nanoparticle. The surface of the nanoparticle contains antibodies. The number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, for example, a liposome, can more effectively exert a therapeutic effect on tumor and improve multidrug resistance of tumor, thereby overcoming the technical prejudice that it is commonly considered that the more antibodies on a surface of a liposome, the better the target cell binding effect, and laying a foundation for further clinical development.An antibody-conjugated liposome, particularly a nanoparticle, the surface of which contains antibodies, and the number of the antibodies is 5-60, preferably 5-50, and more preferably 5-40. The nanoparticle, such as a liposome, can more effectively exert a therapeutic effect on tumors and reduce the multidrug resistance of tumors. This overcomes the generally accepted technical bias that more antibodies on the surface of a liposome lead to better binding with target cells, thereby laying the foundation for further clinical development.

The invention provides a B cell or CD11b + cell targeted nano-liposome and application thereof, and the B cell or CD11b + cell targeted nano-liposome is prepared from polyethylene glycol and derivatives thereof, cholesterol, phosphate fat and derivatives thereof which are self-assembled in different proportions and selectively act on B cells or CD11b + cells in a targeted manner under the condition that bioactive molecules are not coupled. And various anti-cancer new dosage forms, vaccine dosage forms and gene therapy vectors are prepared based on the nano-liposome capable of targeting B cells or CD11b + cells.

The application discloses a kind of nanomaterial and its preparation method and application, the nanomaterial includes exosome and liposome;The exosome expresses immune checkpoint, the exosome is derived from brain glioma cell;The liposome is loaded with I type photosensitizer.The application is by PDT, immune checkpoint and brain glioma cell exosome antigen three tubes simultaneously to remodel tumor local immune microenvironment, greatly improve the efficiency of cancer immunotherapy, can activate strong anti brain glioma immune response and overcome immune escape.